Advancing early detection of type 1 diabetes through screening

Type 1 diabetes (T1D) is a lifelong autoimmune condition that often progresses silently for years before clinical symptoms emerge. Today, an estimated 9–10 million people worldwide live with T1D, and incidence continues to rise across both pediatric and adult populations. Projections suggest prevalence could increase by 27–92% by 2040, creating a growing public health and economic challenge. Compounding this issue, up to 90% of new diagnoses occur in individuals without a family history, limiting the impact of traditional risk based screening approaches.

This whitepaper explores how advances in early detection, specifically islet autoantibody screening are reshaping the T1D care pathway. Identifying individuals in presymptomatic stages can occur years before clinical diagnosis, opening a critical window for monitoring, education, and proactive intervention. Early identification is strongly associated with a reduced risk of diabetic ketoacidosis (DKA) at diagnosis, a life threatening and costly emergency that remains common across the UK and EU, particularly among children. Beyond clinical outcomes, the paper examines the substantial economic burden associated with T1D. Diabetes accounts for approximately 12% of global health expenditure. In the UK, total diabetes costs are estimated at £10.7 billion annually, nearly 6% of total NHS spending, with close to 60% driven by largely preventable complications rather than routine care. Without intervention, overall costs are projected to rise to nearly £18 billion by 2035. Similar spending patterns are seen across Europe, where inpatient admissions and long term complications consume a significant share of healthcare resources.

As healthcare systems across the UK and EU increasingly prioritize precision medicine, population level screening, and preventive chronic disease management, early T1D detection represents a powerful opportunity to improve outcomes while reducing downstream costs. This whitepaper outlines how Revvity’s type 1 diabetes screening capabilities support these goals, helping healthcare organizations move from reactive diagnosis to proactive care.

Download the whitepaper to gain insight into the clinical, economic, and system level impact of early T1D screening and its role in shaping the future of diabetes management.

This testing service has not been cleared or approved by the U.S. Food and Drug Administration. Testing services may not be licensed in accordance with the laws in all countries. The availability of specific test offerings is dependent upon laboratory location. The content on this page is provided for informational purposes only, not as medical advice. It is not intended to substitute the consultation, diagnosis, and/or treatment provided by a qualified licensed physician or other medical professionals.